This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Philogen S.p.a.. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Verena Gafner: Innovator in Targeted Cancer Therapy
Introduction
Verena Gafner is a prominent inventor based in Bern, Switzerland. She has made significant contributions to the field of cancer therapy through her innovative research and development of targeted therapeutic agents. Her work focuses on creating conjugates that can effectively target neoplastic growth and angiogenesis.
Latest Patents
Verena Gafner holds a patent for a fusion protein of antibody L19 against fibronectin ED-B and interleukin 12. This conjugate is designed for targeting therapeutic or diagnostic agents to cells or tissues in the body, particularly in areas of neoplastic growth or angiogenesis. The patent outlines the use of this conjugate for in vivo diagnosis or therapy, including inhibiting tumor growth, metastasis, and angiogenesis, as well as treating cancer. The conjugate comprises a therapeutic or diagnostic agent as an oligomeric protein, such as a heterodimeric protein, where the first and second subunits are conjugated to specific binding members, like an antibody fragment such as scFv.
Career Highlights
Verena Gafner is associated with Philogen S.p.a., where she continues to advance her research in targeted therapies. Her innovative approach has positioned her as a key figure in the development of new cancer treatments.
Collaborations
Some of her notable coworkers include Dario Neri and Cornelia Halin, who collaborate with her in the pursuit of groundbreaking advancements in cancer therapy.
Conclusion
Verena Gafner's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. Her contributions through her patent and collaboration with esteemed colleagues highlight her commitment to improving therapeutic outcomes for patients.